BLISS GVS PHARMA GHANA, a major pharmaceutical company in the country, has donated a significant amount of antimalarials and other essential medicines to the Sunyani Regional Hospital to help combat the disease.
Malaria is a major health challenge in Ghana. The disease is a leading cause of illness and death in the country, particularly among children under the age of five.
To help address this critical public health issue, BLISS GVS PHARMA GHANA has continued to donate antimalarials to the Sunyani Regional Hospital, to support prevention and control efforts in the country.
The donation includes a range of antimalarial medications, including artemisinin-based combination therapies (ACTs), like LONART, and P-ALAXIN which are recommended by the WHO as the first-line treatment for uncomplicated malaria.
GSUNATE Injections, GSUNATE suppositories, CLAMOXIN Injections, and GACET suppositories are the other medicines donated. The value of medicines donation is 100,000 Ghanaian cedis.
“Our donation of antimalarials reflects our ongoing efforts to support the fight against malaria and to ensure that people have access to the medications they need to stay healthy”, said Mr. Augustine, representative of BLISS GVS PHARMA GHANA, Sunyani Region.
The managing director of Bliss GVS Pharma, Mr. Gagan Sharma, is very concerned about the usage of fake antimalarial treatments, thus the company’s main objective is to provide high-quality medications to combat the disease,” he stated.
BLISS GVS PHARMA GHANA’s antimalarial donation is part of the company’s ACT for Africa campaign to eradicate malaria in Ghana and other African countries.
The donation was received by the Hospital Administrator of the Sunyani Regional Hospital, Mr. Samuel Dodzi. Mr. Dodzi expressed his gratitude to Bliss GVS Pharma for the donation and noted that the anti-malaria drugs would go a long way in helping the hospital to provide effective treatment to patients.
The company’s philanthropic efforts reflect the private sector’s role in advancing global health equity and supporting the government to reduce the burden of infectious diseases and improve health outcomes for all.